CONy 2020 | The problem with assumptions in epilepsy clinical trials
Daniel Goldenholz
• 26 Oct 2020
Daniel Goldenholz, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, discusses the challenges with the current assumptions in epilepsy clinical trials. These assumptions presume that a participant’s seizure frequency is static, whereas in reality, a participant’s seizure frequency is variable. Through the use of seizure diaries, this has been illustrated. Therefore, clinical trials need to adapt to limit mistakes and the possibility of misclassifying treatments. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
Disclosures
Daniel Goldenholz has received grants from NIH and BIDMC. He is on the advisory board for Magic Leap and Epilepsy AI.
